SEARCH

SEARCH BY CITATION

References

  • 1
    Primary Immunodeficiency Diseases. Report of an IUIS Scientific Committee. Clin Exp Immunol 1999; 118:128.
  • 2
    Eibl MM, Wedgwood RJ. Intravenous immunoglobulin: a review. Immunodef Rev 1989; 1 (Suppl.):142.
  • 3
    Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Biodrugs 2007; 21:10516.
  • 4
    Gardulf A, Hammarström L, Smith CIE. Home treatment for hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338:1626.
  • 5
    Gardulf A, Andersen V, Björkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:3659.
  • 6
    Gardulf A, Björvell H, Gustafson R et al. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency 1993; 4:814.
  • 7
    Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet 1993; 342:14323.
  • 8
    Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996; 98:112731.
  • 9
    Gustafson R, Gardulf A, Granert C et al. Prophylactic therapy for selective IgA deficiency. Lancet 1997; 350:865.
  • 10
    Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998; 79:4851.
  • 11
    Chapel HM, Spickett GP, Ericson D et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94100.
  • 12
    Hansen S, Gustafson R, Smith CIE et al. Subcutaneous IgG infusions in patients with primary antibody deficiencies: decreased time of delivery with maintained safety. Clin Immunol 2002; 104:23741.
  • 13
    Grunebaum E, Levy Y, Shoenfeld Y. Novel aspects of hypogammaglobulinemic states: subcutaneous immunoglobulin treatment. Isr Med Assoc J 2002; 4:2889.
  • 14
    Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112:17.
  • 15
    Gardulf A, Nicolay U, Asensio O et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies − a prospective, multi-national study. J Clin Immunol 2006; 26:17785.
  • 16
    Ochs HD, Gupta S, Kiessling P et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:26573.
  • 17
    Gardulf A, Björvell H, Gustafson R et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993; 92:2004.
  • 18
    Gardulf A, Björvell H, Andersen V et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21:91727.
  • 19
    Gardulf A, Nicolay U, Asensio O et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:93641.
  • 20
    Nicolay U, Kiessling P, Berger M et al. Health-related quality of life in patients with primary immunodeficiencies in North America receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:6572.
  • 21
    Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:43442.
  • 22
    Kittner JM, Grimbacher B, Wulff W et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006; 26:4005.
  • 23
    Gardulf A, Borte M, Ochs HD et al. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2007; 126:818.
  • 24
    Lee ML, Poon WY, Kingdon HS. A two-phase linear regression model for biologic half-life data. J Lab Clin Med 1990; 115:7458.
  • 25
    International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Guideline for clinical safety data management: definitions and standards for expedited reporting (III/3375/93) and US regulations (FDA 21 CFR, 312.32). London: European Medicines Agency (EMEA).
  • 26
    Mankarious S, Lee M, Fischer S et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988; 112:63440.
  • 27
    Fischer SH, Ochs HD, Wedgwood RJ et al. Survival of antigen-specific antibody following administration of intravenous immunoglobulin in patients with primary immunodeficiency diseases. Monogr Allergy 1988; 23:22535.
  • 28
    Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13:1110.
  • 29
    Lever AM, Yap PL, Cuthbertson B et al. Increased half-life of gammaglobulin after prolonged intravenous replacement therapy. Clin Exp Immunol 1987; 67:4416.
  • 30
    Thampakkul S, Ballow M. Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency. Immunol Allergy Clin North Am 2001; 21:16584.
  • 31
    Waniewski J, Gardulf A, Hammarström L. Bioavailability of gammaglobulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14:907.
  • 32
    Smith GN, Griffiths B, Mollison D et al. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1972; 1:120812.
  • 33
    Yu ZY, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody mediated autoimmune diseases. N Engl J Med 1999; 340:2278.
  • 34
    Alyanakian MA, Bernatowska E, Scherrmann JM et al. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang 2003; 84:18892.
  • 35
    Ballow M, Berger M, Bonilla FA et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex(TM), 10%). Vox Sang 2003; 84:20210.
  • 36
    Morell A. Pharmacokinetics of intravenous immunoglobulin preparations. In: LeeM, StrandV, eds. Intravenous immunoglobulins in clinical practice. New York: M. Dekker Inc., 1997:118.
  • 37
    Schiff RI. Half-life and clearance of pH 6.8 and pH 4·25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev Infect Dis Suppl 1986; 4:44956.
  • 38
    Webster AD, Latif AA, Brenner MK et al. Evaluation of test immunization in the assessment of antibody deficiency syndromes. Br Med J (Clin Res Ed) 1984; 288:18646.